

Migraine Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/MDE32B7F51EEN.html>

Date: January 2018

Pages: 144

Price: US\$ 3,480.00 (Single User License)

ID: MDE32B7F51EEN

Abstracts

Report Summary

Migraine Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Migraine Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Migraine Drugs 2013-2017, and development forecast 2018-2023

Main market players of Migraine Drugs in EMEA, with company and product introduction, position in the Migraine Drugs market

Market status and development trend of Migraine Drugs by types and applications

Cost and profit status of Migraine Drugs, and marketing status

Market growth drivers and challenges

The report segments the EMEA Migraine Drugs market as:

EMEA Migraine Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe
Middle East
Africa

EMEA Migraine Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Sumatriptan
Zolmitriptan
Rizatriptan
Other Drug

EMEA Migraine Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals
Clinics
Household Use
Others

EMEA Migraine Drugs Market: Players Segment Analysis (Company and Product introduction, Migraine Drugs Sales Volume, Revenue, Price and Gross Margin):

Allergan
Merck
Pfizer
Teva
Pfizer
Johnson & Johnson
Endo International
GlaxoSmithKline
Impax
Abbott
Bayer
Eli Lilly
Ethypharm
Kowa Pharmaceuticals America
Winston Pharmaceuticals
AstraZeneca

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and

individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF MIGRAINE DRUGS

- 1.1 Definition of Migraine Drugs in This Report
- 1.2 Commercial Types of Migraine Drugs
 - 1.2.1 Sumatriptan
 - 1.2.2 Zolmitriptan
 - 1.2.3 Rizatriptan
 - 1.2.4 Other Drug
- 1.3 Downstream Application of Migraine Drugs
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Household Use
 - 1.3.4 Others
- 1.4 Development History of Migraine Drugs
- 1.5 Market Status and Trend of Migraine Drugs 2013-2023
 - 1.5.1 EMEA Migraine Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Migraine Drugs Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Migraine Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Migraine Drugs in EMEA by Regions
 - 2.2.1 Consumption Volume of Migraine Drugs in EMEA by Regions
 - 2.2.2 Revenue of Migraine Drugs in EMEA by Regions
- 2.3 Market Analysis of Migraine Drugs in EMEA by Regions
 - 2.3.1 Market Analysis of Migraine Drugs in Europe 2013-2017
 - 2.3.2 Market Analysis of Migraine Drugs in Middle East 2013-2017
 - 2.3.3 Market Analysis of Migraine Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Migraine Drugs in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Migraine Drugs in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Migraine Drugs by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Migraine Drugs in EMEA by Types
 - 3.1.2 Revenue of Migraine Drugs in EMEA by Types

- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Migraine Drugs in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Migraine Drugs in EMEA by Downstream Industry
- 4.2 Demand Volume of Migraine Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Migraine Drugs by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Migraine Drugs by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Migraine Drugs by Downstream Industry in Africa
- 4.3 Market Forecast of Migraine Drugs in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF MIGRAINE DRUGS

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Migraine Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 MIGRAINE DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Migraine Drugs in EMEA by Major Players
- 6.2 Revenue of Migraine Drugs in EMEA by Major Players
- 6.3 Basic Information of Migraine Drugs by Major Players
 - 6.3.1 Headquarters Location and Established Time of Migraine Drugs Major Players
 - 6.3.2 Employees and Revenue Level of Migraine Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 MIGRAINE DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Allergan
 - 7.1.1 Company profile

- 7.1.2 Representative Migraine Drugs Product
- 7.1.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Allergan
- 7.2 Merck
 - 7.2.1 Company profile
 - 7.2.2 Representative Migraine Drugs Product
 - 7.2.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Merck
- 7.3 Pfizer
 - 7.3.1 Company profile
 - 7.3.2 Representative Migraine Drugs Product
 - 7.3.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Pfizer
- 7.4 Teva
 - 7.4.1 Company profile
 - 7.4.2 Representative Migraine Drugs Product
 - 7.4.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Teva
- 7.5 Pfizer
 - 7.5.1 Company profile
 - 7.5.2 Representative Migraine Drugs Product
 - 7.5.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Pfizer
- 7.6 Johnson & Johnson
 - 7.6.1 Company profile
 - 7.6.2 Representative Migraine Drugs Product
 - 7.6.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.7 Endo International
 - 7.7.1 Company profile
 - 7.7.2 Representative Migraine Drugs Product
 - 7.7.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Endo International
- 7.8 GlaxoSmithKline
 - 7.8.1 Company profile
 - 7.8.2 Representative Migraine Drugs Product
 - 7.8.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
- 7.9 Impax
 - 7.9.1 Company profile
 - 7.9.2 Representative Migraine Drugs Product
 - 7.9.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Impax
- 7.10 Abbott
 - 7.10.1 Company profile
 - 7.10.2 Representative Migraine Drugs Product
 - 7.10.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Abbott
- 7.11 Bayer

- 7.11.1 Company profile
- 7.11.2 Representative Migraine Drugs Product
- 7.11.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Bayer
- 7.12 Eli Lilly
 - 7.12.1 Company profile
 - 7.12.2 Representative Migraine Drugs Product
 - 7.12.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.13 Ethypharm
 - 7.13.1 Company profile
 - 7.13.2 Representative Migraine Drugs Product
 - 7.13.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Ethypharm
- 7.14 Kowa Pharmaceuticals America
 - 7.14.1 Company profile
 - 7.14.2 Representative Migraine Drugs Product
 - 7.14.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Kowa Pharmaceuticals America
- 7.15 Winston Pharmaceuticals
 - 7.15.1 Company profile
 - 7.15.2 Representative Migraine Drugs Product
 - 7.15.3 Migraine Drugs Sales, Revenue, Price and Gross Margin of Winston Pharmaceuticals
- 7.16 AstraZeneca

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MIGRAINE DRUGS

- 8.1 Industry Chain of Migraine Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF MIGRAINE DRUGS

- 9.1 Cost Structure Analysis of Migraine Drugs
- 9.2 Raw Materials Cost Analysis of Migraine Drugs
- 9.3 Labor Cost Analysis of Migraine Drugs
- 9.4 Manufacturing Expenses Analysis of Migraine Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF MIGRAINE DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Migraine Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/MDE32B7F51EEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MDE32B7F51EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970